January 18, 2017—Patient advocacy groups and private practice oncologists frequently parrot the drug industry about the 340B drug discount program. New research in JAMA Internal Medicine sheds light on why that might be.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)